4,894
Participants
Start Date
October 31, 2004
Primary Completion Date
March 31, 2012
Study Completion Date
June 30, 2016
Cyclophosphamide
"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
Docetaxel
75 mg/m2 IV every 21 days for 6 cycles
Gemcitabine
2000 mg/m2 IV every 14 days for 4 cycles
Paclitaxel
175 mg/m2 IV every 14 days for 4 cycles
Doxorubicin
"Group 1: 50 mg/m2 IV every 21 days for 6 cycles~Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
Chestnut Hill Healthcare Cancer Center, Philadelphia
Robert and Carol Weissman Cancer Center at Martin Memorial, Stuart
Lurleen Wallace Comprehensive Cancer at University of Alabama - Birmingham, Birmingham
Community Oncology Group at Cleveland Clinic Cancer Center, Independence
Altru Cancer Center at Altru Hospital, Grand Forks
Methodist Estabrook Cancer Center, Omaha
Madigan Army Medical Center - Tacoma, Tacoma
Providence Cancer Center, Anchorage
Lucille P. Markey Cancer Center at University of Kentucky, Lexington
South Shore Hospital, South Weymouth
CCOP - Northern New Jersey, Hackensack
Blumenthal Cancer Center at Carolinas Medical Center, Charlotte
National Cancer Institute (NCI)
NIH
NSABP Foundation Inc
NETWORK